Comment
Author: Admin | 2025-04-28
In weekly mean pain scores was significantly greater with pregabalin compared to placebo for 10 of the 15 weeks; the patient global impression of change was also significantly improved in patients receiving pregabalin (53.1%) compared to placebo (29.5%). The authors reported a large placebo effect, particularly at non-US study centers; however, significance of this is unknown (Arnold 2016).AdministrationImmediate release: May be administered with or without food.Extended release: Administer once daily after an evening meal; swallow whole, do not split, crush, or chew. A missed dose should be taken before bedtime following a snack. If missed before bedtime, administer in the morning with a meal. If missed in the morning, wait until the evening meal to take the next scheduled dose. StorageStore at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Pregabalin Images pregabalin 25 mg pregabalin 50 mg pregabalin 75 mg pregabalin 100 mg pregabalin 150 mg pregabalin 200 mg Drug InteractionsAlcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Monitor therapyAlizapride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyAngiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. Monitor therapyAzelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). Avoid combinationBlonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Consider therapy modificationBrexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Monitor therapyBrimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Monitor therapyBromopride: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyBromperidol: May enhance the CNS depressant effect of CNS Depressants. Avoid combinationBuprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Consider therapy modificationCannabidiol: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyCannabis: May enhance the CNS depressant effect of CNS Depressants. Monitor therapyChlormethiazole: May enhance the CNS depressant effect of CNS
Add Comment